Description: Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Home Page: www.esperion.com
ESPR Technical Analysis
3891 Ranchero Drive
Ann Arbor,
MI
48108
United States
Phone:
734 887 3903
Officers
| Name | Title |
|---|---|
| Mr. Sheldon L. Koenig | Pres, CEO & Director |
| Dr. JoAnne Micale Foody FACC, M.D. | Chief Medical Officer |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer |
| Mr. Kenneth J. Fiorelli | Chief Technical Operations Officer |
| Mr. Benjamin O. Looker | Gen. Counsel |
| Ms. Betty Jean Swartz | Chief Strategy Officer |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 98.4236 |
| Price-to-Sales TTM: | 5.982 |
| IPO Date: | 2013-06-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 218 |